The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | Ibrutinib and venetoclax: a powerful combination in frontline and relapsed CLL
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Nitin Jain, MD, from the MD Anderson Cancer Center, Houston, TX, discusses his trial (NCT02756897) examining the synergistic effect of venetoclax and ibrutinib in high risk chronic lymphocytic leukemia (CLL). Current data from this study show impressive rates of minimal residual disease negativity, demonstrating the potency of this combination and the great potential of the therapy.
